Aardvark Therapeutics (AARD) Competitors $7.74 -1.16 (-13.03%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock AARD vs. COGT, LENZ, BCAX, QURE, ABCL, PRTA, CRON, DNTH, GHRS, and BCYCShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Cogent Biosciences (COGT), LENZ Therapeutics (LENZ), Bicara Therapeutics (BCAX), uniQure (QURE), AbCellera Biologics (ABCL), Prothena (PRTA), Cronos Group (CRON), Dianthus Therapeutics (DNTH), GH Research (GHRS), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Cogent Biosciences LENZ Therapeutics Bicara Therapeutics uniQure AbCellera Biologics Prothena Cronos Group Dianthus Therapeutics GH Research Bicycle Therapeutics Cogent Biosciences (NASDAQ:COGT) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Is COGT or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Aardvark Therapeutics N/A N/A N/A Does the MarketBeat Community favor COGT or AARD? Cogent Biosciences received 285 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Aardvark Therapeutics an outperform vote while only 70.22% of users gave Cogent Biosciences an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes29070.22% Underperform Votes12329.78% Aardvark TherapeuticsOutperform Votes5100.00% Underperform VotesNo Votes Do analysts prefer COGT or AARD? Cogent Biosciences presently has a consensus price target of $14.43, indicating a potential upside of 122.32%. Aardvark Therapeutics has a consensus price target of $31.50, indicating a potential upside of 262.07%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, COGT or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$1.94-3.35Aardvark TherapeuticsN/AN/AN/AN/AN/A Does the media prefer COGT or AARD? In the previous week, Aardvark Therapeutics had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Aardvark Therapeutics and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.05 beat Aardvark Therapeutics' score of 0.94 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAardvark Therapeutics beats Cogent Biosciences on 6 of the 9 factors compared between the two stocks. Remove Ads Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark Therapeutics IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.51M$2.73B$5.63B$7.83BDividend YieldN/A13.10%4.57%4.00%P/E RatioN/A11.7623.3318.67Price / SalesN/A2,341,095.51388.4691.01Price / CashN/A16.2238.1634.64Price / BookN/A2.996.894.23Net IncomeN/A$46.61M$3.20B$247.15M7 Day Performance-21.90%-1.11%-3.02%-2.17%1 Month Performance-39.20%-2.58%1.63%-5.68%1 Year PerformanceN/A1.81%9.74%-0.67% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$7.74-13.0%$31.50+307.0%N/A$165.51MN/A0.0018Analyst ForecastQuiet Period ExpirationNews CoveragePositive NewsGap DownCOGTCogent Biosciences2.3849 of 5 stars$6.61+2.2%$14.43+118.3%+1.4%$752.55MN/A-2.6780Positive NewsLENZLENZ Therapeutics1.7456 of 5 stars$26.53+1.7%$41.67+57.1%+21.6%$730.72MN/A-5.56110BCAXBicara TherapeuticsN/A$13.40+2.3%$36.50+172.4%N/A$729.17MN/A0.0032Earnings ReportAnalyst ForecastNews CoverageGap DownQUREuniQure2.6727 of 5 stars$13.13-3.8%$38.89+196.2%+142.7%$710.03M$27.12M-2.65500ABCLAbCellera Biologics2.4371 of 5 stars$2.36-2.5%$7.00+196.6%-47.4%$703.25M$28.83M-3.87500Positive NewsPRTAProthena3.2996 of 5 stars$13.01-2.7%$55.00+322.8%-48.3%$700.29M$135.16M-5.66130Analyst RevisionNews CoveragePositive NewsCRONCronos Group1.8881 of 5 stars$1.83+1.7%$3.00+63.9%-32.2%$700.03M$117.62M-14.08450DNTHDianthus Therapeutics1.3692 of 5 stars$19.87+8.8%$54.33+173.4%-35.1%$638.32M$6.24M-7.9580GHRSGH Research2.6562 of 5 stars$12.25+1.6%$30.86+151.9%+14.4%$637.34MN/A-15.5110BCYCBicycle Therapeutics1.9361 of 5 stars$9.19+5.3%$29.14+217.1%-62.6%$635.97M$35.28M-2.79240 Remove Ads Related Companies and Tools Related Companies COGT Alternatives LENZ Alternatives BCAX Alternatives QURE Alternatives ABCL Alternatives PRTA Alternatives CRON Alternatives DNTH Alternatives GHRS Alternatives BCYC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AARD Stock Free AARD Stock Alerts